Pembroliuzmab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience. This is an ASCO Meeting Abstract from the 2017 Gastrointestinal Cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback